Background: A left ventricular assist device (LVAD) is used to support patients with end-stage heart failure.

Aims: To examine the role of comorbidities and complications in predicting in-hospital mortality since the introduction of continuous flow (CF)-LVAD.

Methods: The Nationwide Inpatient Sample was queried from 2010 to 2014 using International Classification of Disease-9 code for LVAD among patients 18 years or older. The sample consisted of 2,359 patients (mean age = 55 ± 13.7 years, 76.8% men, 59.3% Caucasian).

Results: Comparative analysis revealed mortality did not differ from 2010 to 2014 (p = 0.653). Increases in comorbidities of atrial fibrillation, acute kidney injury, mechanical ventilation, body mass index ≥ 25, cerebrovascular disease, and mild liver disease were evidenced over the 5-year period (p values ≤ 0.049). Multivariate analysis showed that significant predictors of mortality were comorbid hemodialysis (AOR = 7.62, 95% CI [4.78, 12.27]), cerebrovascular disease (AOR = 5.38, 95% CI [3.49, 8.26]), mechanical ventilation (AOR = 3.83, 95% CI [2.84, 5.18]), mild liver disease (AOR = 1.96, 95% CI [1.38, 2.76]), and acute kidney injury (AOR = 1.62, 95% CI [1.16, 2.28]). Predictive complications included disseminated intravascular coagulation (AOR = 6.41, 95% CI [2.79, 6.84]), sepsis (AOR = 4.37, 95% CI [2.79, 6.84]), septic shock (AOR = 3.9, 95% CI [2.11, 7.59]), and gastrointestinal bleed (AOR = 1.81, 95% CI [1.11, 2.93]).

Conclusions: CF-LVADs have not reduced mortality, possibly due to utilization in patients with comorbid conditions. Future trials are necessary for improved patient selection and reduced post-procedural complications.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11845-020-02246-yDOI Listing

Publication Analysis

Top Keywords

95%
9
in-hospital mortality
8
left ventricular
8
ventricular assist
8
assist device
8
2010 2014
8
acute kidney
8
kidney injury
8
mechanical ventilation
8
cerebrovascular disease
8

Similar Publications

Article Synopsis
  • The study measured fibrinogen fluorescence at temperatures between 20 and 80 degrees Celsius across different pH levels.
  • It was found that raising the temperature from 20 to 40 degrees Celsius did not change the structure of fibrinogen in solutions with pH between 4.5 and 9.3.
  • However, temperatures between 40 to 50 degrees Celsius caused some structural changes in neutral solutions, and temperatures above 50-55 degrees Celsius led to significant denaturation of the fibrinogen molecule.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!